Product ID I4802Cas No. 220127-57-1Purity ≥98%

• Description
• Product Info
• Shipping and Storage
• Downloads
• References

Description

Imatinib is an anticancer chemotherapeutic compound that inhibits Abl, c-Kit, and PDGFR; it is used clinically to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL). In cellular assays, imatinib accelerates erythroblast differentiation and inhibits melanogenesis.

Product Info

Cas No.PurityFormulaFormula Wt.Chemical NameIUPAC NameMelting PointSolubilityAppearance

220127-57-1

≥98%

C29H31N7O • CH3SO3H

589.718

methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide

methanesulfonicacid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide

226C

Ethanol (0.2 mg/ml), DMSO (10 mg/ml), Dimethyl Formamide, PBS (2 mg/mL)

White to off white powder

Shipping and Storage

Store TempShip Temp

Ambient

Ambient

Downloads

MSDSInfo Sheet

I4802 MSDS PDF

I4802 Info Sheet PDF

References

Wang Y, Zhao Y, Liu L, et al. Inhibitory effects of imatinib mesylate on human epidermal melanocytes. Clin Exp Dermatol. 2014 Mar;39(2):202-8. PMID: 24479586.

Dallard D, Gay J, Descarpentries C, et al. Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket. PLoS One. 2013 Apr 23;8(4):e60961. PMID: 23637779.

Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003 Feb;4(2):75-85. PMID: 12573349.

>>> 更多资讯详情请访问蚂蚁淘商城